The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa
Endocrine Reviews · 07.05.2024 · 45 (3) · 379-413
DOI: 10.1210/endrev/bnad037 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine Reviews, online erschienen am 16.01.2024. Verfasst von Julio Rosenstock und 5 weiteren Autor:innen. Beteiligte Einrichtung: Velocity Clinical Research at Medical City, Dallas, TX 75230, USA. Hauptthemen laut MEDLINE: Hypoglycemic Agents. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Basal insulin continues to be a vital part of therapy for many people with diabetes. First attempts to prolong the duration of insulin formulations were through the development of suspensions that required homogenization prior to injection. These insulins, which required once- or twice-daily injections, introduced wide variations in insulin exposure contributing to unpredictable effects on glycemia. Advances over the last 2 decades have resulted in long-acting, soluble basal insulin analogues with prolonged and less variable pharmacokinetic exposure, improving their efficacy and safety, notably by reducing nocturnal hypoglycemia. However, adherence and persistence with once-daily basal insulin treatment remains low for many reasons including hypoglycemia concerns and treatment burden. A soluble basal insulin with a longer and flatter exposure profile could reduce pharmacodynamic variability, potentially reducing hypoglycemia, have similar efficacy to once-daily basal insulins, simplify dosing regimens, and improve treatment adherence. Insulin icodec (Novo Nordisk) and insulin efsitora alfa (basal insulin Fc [BIF], Eli Lilly and Company) are 2 such insulins designed for once-weekly administration, which have the potential to provide a further advance in basal insulin replacement. Icodec and efsitora phase 2 clinical trials, as well as data from the phase 3 icodec program indicate that once-weekly insulins provide comparable glycemic control to once-daily analogues, with a similar risk of hypoglycemia. This manuscript details the technology used in the development of once-weekly basal insulins. It highlights the clinical rationale and potential benefits of these weekly insulins while also discussing the limitations and challenges these molecules could pose in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Velocity Clinical Research at Medical City, Dallas, TX 75230, USA.
- Lilly Diabetes and Obesity, Eli Lilly and Company, Indianapolis, IN 46225, USA.
- School of Medicine, University of Dundee, Dundee DD1 9SY, Scotland, UK.
ORCID-Profile: Julio Rosenstock
Förderung
- Eli Lilly and Company
Zitieren
APA
Rosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L., & McCrimmon, R. J. (2024). The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocrine Reviews, 45(3), 379-413. https://doi.org/10.1210/endrev/bnad037
Vancouver
Rosenstock J, Juneja R, Beals JM, Moyers JS, Ilag L, McCrimmon RJ. The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocrine Reviews. 2024;45(3):379-413. doi:10.1210/endrev/bnad037
BibTeX
@article{Rosenstock2024,
author = {Rosenstock, Julio and Juneja, Rattan and Beals, John M and Moyers, Julie S and Ilag, Liza and McCrimmon, Rory J},
title = {The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa},
journal = {Endocrine Reviews},
year = {2024},
volume = {45},
number = {3},
pages = {379--413},
doi = {10.1210/endrev/bnad037}
}
EUVIMED